Skip to main content
Premium Trial:

Request an Annual Quote

Anthony Mattacchione, Gerald Herman

Bruker said that Anthony Mattacchione will resign as chief financial officer and senior VP, effective Mar. 16, 2018. Mattacchione has accepted a position as CFO of Albany Molecular Research, commencing in April 2018. Gerald Herman, currently vice president and corporate controller at Bruker, will also serve as Bruker's principal accounting officer, effective immediately. Herman joined the firm in 2016 as VP and corporate controller. Prior to that, he served as corporate VP of clinical operations of Parexel from 2014 to February 2016, and before that, corporate VP of Parexel from 2008 to 2013. Herman has also served as VP-corporate controller of Presstek.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.